BIO 2013 Tuesday Roundup: Reimbursement Reigns, Industry Innovation, New Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Our survey of news and notes from the second day of the BIO conference includes discussions of changes in the way pharma negotiates milestones, big ambitious projects to solve industry “dysfunction,” and a next-generation antibody developer pushing toward the clinic.